Lusaris Therapeutics
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $60M
Investors
- 4
About Lusaris Therapeutics
Founded in 2021 and based in Massachusetts, US, Lusaris Therapeutics, Inc. is a biotechnology company focused on developing next-generation serotonergic neuroplastogen medicines for the treatment of severe neuropsychiatric and neurological illnesses. As of 2022, Andrew Levin is the interim CEO of the company. In November 2022, Lusaris Therapeutics, Inc. The company provides its lead product, LSR-1019, which is a sublingual formulation of 5-MeO-DMT, an acting and clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. The firm's products also include LSR-2000, which is a late-stage discovery program evaluating serotonergic neuroplastogens for the prevention of migraines and cluster headaches, and LSR-3000, which is a discovery program focused on developing therapies suitable for chronic dosing by maintaining broad serotonergic receptor activation.
Who invested in Lusaris Therapeutics
4 investors across 1 round
See all investors in Lusaris Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 13, 2022
Amount
$60M
Investors
Questions about Lusaris Therapeutics
Who invested in Lusaris Therapeutics?
Lusaris Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lusaris Therapeutics raised?
Lusaris Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lusaris Therapeutics last raise money?
Lusaris Therapeutics's most recent round on record is a Series A, in Oct 2022.
What does Lusaris Therapeutics do?
Founded in 2021 and based in Massachusetts, US, Lusaris Therapeutics, Inc.
Where is Lusaris Therapeutics headquartered?
Lusaris Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Lusaris Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Lusaris Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Lusaris Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.